RxDoctor Payments Data

Amanda Jones

Nurse Practitioner · Elkins, WVNPI 1073999371

Payments from drug & device makers

What this record shows

20 manufacturers reported payments, led by Midmark Corporation at 50.6% of the total. Reporting peaked in 2024 at $1,531 and has fallen 98.1% since, to $29 in 2025. Among nurse practitioner clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,915in general payments, 2019–2025

Across 88 payments — averaging $33.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Midmark Corporation$1K
  • Novo Nordisk$519
  • AstraZeneca$167
  • Boehringer Ingelheim$160
  • Pfizer$86
  • Johnson & Johnson$69
  • plus $440 from 14 others

What the payments were for

  • Travel & lodging$1,30445%
  • Food & beverage$1,61155%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,915 in reported general payments places this provider in the 90th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$625
Medicare patients
15
Services billed
26

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$37,189
JardianceEmpagliflozin19$21,826
JanuviaSitagliptin Phosphate14$19,450
VraylarCariprazine Hcl11$14,961
Tresiba Flextouch U-100Insulin Degludec14$6,779
SymbicortBudesonide/Formoterol Fumarate17$5,096
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,917
Albuterol Sulfate HfaAlbuterol Sulfate36$1,438
Omeprazole53$469
Levothyroxine Sodium54$451
Atorvastatin Calcium77$447
Famotidine29$403
Pantoprazole Sodium50$395
Lisinopril65$383
Metoprolol Succinate17$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$519$37,18918 claims
Boehringer IngelheimJardiance$160$21,82619 claims
MerckJanuvia$17$19,45014 claims
AstraZenecaSymbicort$167$5,09617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Elkins

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →